Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / CCL18

CCL18

Basics

Aliases:
This biomarker is also known as:
  • CKb7,
  • MIP4,
  • chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated),
  • small inducible cytokine subfamily A (Cys-Cys), member 18, pulmonary and activation-regulated,
  • PARC,
  • MIP-4,
  • alternative macrophage activation-associated CC chemokine 1,
  • DCCK1,
  • small inducible cytokine A18,
  • Macrophage inflammatory protein 4,
  • chemokine (C-C), dendritic,
  • pulmonary and activation-regulated chemokine,
  • AMAC1,
  • Pulmonary and activation-regulated chemokine,
  • AMAC-1,
  • Dendritic cell chemokine 1,
  • SCYA18,
  • dendritic cell chemokine 1,
  • CC chemokine ligand 18,
  • CC chemokine PARC,
  • Small-inducible cytokine A18,
  • DC-CK1,
  • macrophage inflammatory protein 4,
  • C-C motif chemokine 18,
  • Alternative macrophage activation-associated CC chemokine 1,
  • small-inducible cytokine A18,

View in BioMuta

Description…

CCL18, also known as MIP-4, is a member of the cytokine family, a family of secreted proteins involved in immunoregulatory and inflammatory processes. CCL18 is a Cys-Cys (CC) cytokine, characterized by two adjacent cysteines. CCL18 is a chemotactic factor that attracts lymphocytes but not monocytes or granulocytes. This chemokine attracts naive T lymphocytes toward dendritic cells and activated macrophages in lymph nodes. It may play a role in both humoral and cell-mediated immunity responses.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: CCL18

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: Two
QA State: Curated

Overview

CCL18 has been described in the literature as a potential biomarker for ovarian, bladder, breast, and colorectal cancer. CCL18 has not been identified previously in serum as a lung cancer biomarker, but it was observed up-regulated in lung cancer in the aptamer proteomic technology study (Ostroff et al, 2010).

Performance Comment

CCL18, also known as MIP-4, is a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.

Prostate

Attributes

Phase: One
QA State: Under Review

Overview

Performance Comment

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 02/12/2015

Please register for the 29th EDRN Steering Committee Meeting in Atlanta, GA from March 31-April 2, 2015. The registration page has information about booking hotel rooms and a draft agenda of the meeting.

Announcement